Results 241 to 250 of about 52,905 (310)

Is AMP‐activated protein kinase activation a central mechanism of cardio‐metabolic outcomes after metabolic and bariatric surgery?

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3480-3490, May 2026.
Abstract Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity. It usually results in spectacular weight loss, associated with improvements of obesity‐associated comorbidities. The mechanisms underlying these benefits are not fully understood but could involve a postoperative activation of the enzyme 5′ AMP‐activated ...
Adrien Delcour, Nathalie Niederhoffer
wiley   +1 more source

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX‐SEMA 2.4 mg, an Italian real‐world study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3623-3631, May 2026.
Abstract Aims To evaluate real‐world clinical use of semaglutide in obese patients, focusing on titration, tolerability and short‐term efficacy. Materials and Methods This retrospective study included obese patients treated with the weekly injectable semaglutide.
Simone Pampanelli   +12 more
wiley   +1 more source

Causal role of genetically predicted impairment of branched‐chain amino acid catabolism on insulin secretion and insulin resistance in type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3849-3860, May 2026.
Abstract Background Elevated branched‐chain amino acids (BCAAs; leucine, valine, isoleucine) are linked to type 2 diabetes (T2D) risk, characterised by defective insulin secretion in pancreatic β‐cell and peripheral insulin resistance. Causative interaction between BCAA metabolism and these two diabetic pathogenesis remains unclear.
Xiangyu Zhou   +4 more
wiley   +1 more source

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction‐Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta‐Analysis of Randomised Clinical Trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4253-4260, May 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity‐management modalities exert weight‐independent hepatic effects remains uncertain.
Matteo Monami   +11 more
wiley   +1 more source

Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case-Control Study. [PDF]

open access: yesMedicina (Kaunas)
Obajed Al-Ali N   +10 more
europepmc   +1 more source

FNDC4 and FNDC5 Attenuate SARS‐CoV‐2 S1‐Induced Inflammatory Responses in Human Adipose Tissue

open access: yesEuropean Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
In obesity, reduced FNDC4 and FNDC5 amplify SARS‐CoV‐2 S1–driven inflammation in visceral adipose tissue. These adipo‐myokines limit adipocyte–macrophage inflammatory signalling, suggesting a protective role against viral‐induced adipose tissue dysfunction.
Gabriela Neira   +11 more
wiley   +1 more source

Serum CTRP3 and CysC correlate with glucose, lipid, and bone metabolism in elderly patients with type 2 diabetes mellitus complicated with osteoporosis

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 5, Page 880-891, May 2026.
Serum levels of CTRP3 and CysC in elderly patients with T2DM and OP are closely associated with glucose‐lipid metabolism, bone mineral density, and bone metabolism markers. Combined detection of these two markers can assist in distinguishing OP in elderly patients with T2DM.
Yi‐Peng Wang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy